




Prothena Corporation plc  
 Investor Relations Department  
 331 Oyster Point Blvd  
 South San Francisco, CA 94080  
 United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: PRTA**

Last Trade:	34.61
Trade Time:	4:00 PM ET Feb 23, 2018
Change:	0.96  (+2.853%)
Day Range	33.36 - 34.70
52-Week Range	27.19 - 70.00
Volume	189,428

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Feb 14, 2018*  
[Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update](#)
- Feb 7, 2018*  
[Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference](#)
- Feb 2, 2018*  
[Prothena Announces Departure of Chief Medical Officer](#)
- Feb 1, 2018*  
[Prothena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14](#)
- Jan 3, 2018*  
[Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference](#)

**Financials** [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 27, 2017*  
[Annual Report \(10-K\)](#)
- Mar 31, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)